Search results
Found 91 matches for
An internationally recognised centre of excellence for biomedical and clinical research and teaching
Oxford vaccine stimulates broad antibody and T cell functions
Clinical Trials Coronavirus COVID-19 Research
17 December 2020
Today, researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
Clinical Trials Coronavirus COVID-19 General Research
8 December 2020
Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
Oxford coronavirus vaccine produces strong immune response in older adults
Clinical Trials Coronavirus COVID-19 General Research
19 November 2020
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
Interferon-b trial shows positive results
Clinical Trials Coronavirus COVID-19 General Research
16 November 2020
A trial of a new inhaled antiviral drug for COVID-19 has shown positive results and the drug is now moving into a larger international phase 3 trial of hospitalised patients.
Trials of Oxford coronavirus vaccine begin in Kenya
Clinical Trials Coronavirus COVID-19 Research
2 November 2020
Kenya has joined the global efforts in search of an effective vaccine for COVID-19 with the start of a trial evaluating the ChAdOx1 nCoV-2019 Oxford coronavirus vaccine.
Global clinical trials of COVID-19 vaccine resume
Clinical Trials Coronavirus COVID-19 Research
23 October 2020
The Food and Drug Administration (FDA) has today authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford coronavirus vaccine in the USA following the trials restarting in the UK, Brazil, South Africa and Japan.
Oxford COVID-19 vaccine follows its programmed genetic instructions, independent analysis finds
Clinical Trials Coronavirus COVID-19 Research
22 October 2020
A team at Bristol University has used recently developed techniques to validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford team.
Britain’s most influential Hindu temple spreads awareness of the PRINCIPLE trial among Indian Community
Clinical Trials Coronavirus COVID-19 Research
21 October 2020
Europe’s BAPS Swaminarayan Sanstha is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.
New trial to treat Covid-19 in care homes using anti-TNF drug begins
Clinical Trials Coronavirus COVID-19 Research
30 September 2020
Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes.
Coronavirus: the road to vaccine roll-out is always bumpy, as 20th-century pandemics show
Clinical Trials Coronavirus COVID-19 General
23 September 2020
Oxford scientists: these are final steps we’re taking to get our coronavirus vaccine approved
Clinical Trials Coronavirus COVID-19 Research
10 September 2020
UK regulator gives green light to clinical trial of hydroxychloroquine to prevent Covid-19 in healthcare workers
Clinical Trials Coronavirus COVID-19 General
30 June 2020
The UK regulator MHRA announced on 26 June that it would again permit recruitment to the COPCOV COVID-19 prevention clinical trial. The MHRA decision came 5 weeks after it reacted immediately to the now-discredited paper published in The Lancet suggesting harms with hydroxychloroquine, and paused recruitment of UK participants. But The Lancet paper was based on fabricated data and was swiftly retracted. After this interruption, recruitment around the globe to COPCOV can now resume.
Trial of Oxford COVID-19 vaccine starts in Brazil
Clinical Trials Coronavirus COVID-19 General
29 June 2020
Volunteers have begun taking part in Latin America’s first clinical trial for a vaccine against COVID-19.
Trial of Oxford COVID-19 vaccine in South Africa begins
Clinical Trials Coronavirus COVID-19 General
24 June 2020
Participants in South Africa’s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.
Oxford University collaborate with Bvlgari to fight COVID-19 and future pandemics
Clinical Trials Coronavirus COVID-19 General
17 June 2020
Bvlgari, the Italian luxury brand, has today announced plans to support research into COVID-19 and vaccine development at Oxford University.
Dexamethasone reduces death in hospitalised patients with severe respiratory
Clinical Trials Coronavirus COVID-19 General Research
16 June 2020
In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
Clinical Trials Coronavirus COVID-19 General
15 June 2020
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
CATALYST trial: Oxford leads part of major COVID-19 drugs trial
Clinical Trials Coronavirus COVID-19 General
10 June 2020
As part of the UK NIHR multi-arm, multi-stage CATALYST Trial, researchers at the University of Oxford will investigate whether administering the anti-inflammatory drug infliximab to patients with COVID-19 can prevent progression to respiratory failure or death.
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
Clinical Trials Coronavirus COVID-19 General Research
5 June 2020
A new statement has been released from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine.
Clinical trials on hydroxychloroquine/ chloroquine in COVID-19. Statement in response to damaging recent events
Clinical Trials Coronavirus COVID-19 General Research
5 June 2020
On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU’s statement in response to these events.